

thermoscientific



The gold standard in prenatal screening


Combined 1st trimester screening
with PAPP-A, Free β hCG and PIGF

ThermoFisher
SCIENTIFIC

First trimester combined screening

Identification of multiple pregnancy complications

The main advantage of the first trimester combined screening approach is the possibility to predict many major fetal and maternal complications early in pregnancy by combining maternal characteristics and history with findings of biochemical and biophysical tests. The result of the screening is calculated via an appropriate risk calculation software and is provided as the individual risk of a pregnant woman.¹



Because quality matters

It is essential that the result of a risk calculation provided to the pregnant woman is as reliable and accurate as possible. This can only be achieved by using the best available methods.



Maternal complications

- Pre-eclampsia
- Gestational diabetes
- Miscarriage
- Stillbirth
- Preterm delivery



Fetal complications

- Open spina bifida
- Major cardiac defects
- Small for gestational age
- Macrosomia
- Trisomy 21, 18 and 13

Biomarkers improve screening performance

With the combined screening approach, a detection rate for trisomy 21 and trisomy 18/13 of 90% and 95% respectively can be achieved at a false positive rate of 3.1%.² In addition to the risk assessment for fetal aneuploidies, biomarkers can also be used to screen for other conditions. Measurement of serum **PIGF** and **AFP** can be performed in the same sample on the same platform and can significantly improve screening performance for

- **pre-eclampsia**
- **fetal growth restriction**
- **preterm birth**^{3,4,5}

B·R·A·H·M·S biomarkers

- Outstanding long-term lot-to-lot stability⁶
- Highest precision for reliable results⁶
- CE marked and FMF approved for all indications



Highly precise biomarker determination

B·R·A·H·M·S Fast Screen pre I plus

- CE marked software for risk calculation of trisomies, pre-eclampsia and neural tube defects
- High quality algorithms based on FMF data and database with over 220 000 pregnancies⁷
- Stable KRYPTOR™ medians⁸



Reliable and effective risk calculation

B·R·A·H·M·S KRYPTOR instruments

- Fully automated random access immunoanalyzer
- Unique and Nobel Prize® winning TRACE™ technology



Fast, efficient and precise measurements

Key elements of calculating the risk

Accurate determination of biochemical and ultrasound markers

PAPP-A and Free β hCG on KRYPTOR Systems


The calculation of the individual risk is based on numerous input factors: measurement of the maternal serum markers PAPP-A and Free β hCG, several ultrasound parameters, and various correction factors from maternal history.

Every single factor has a certain imprecision which influences the risk calculation. The more parameters included in the risk calculation, the higher the total imprecision of the final result – the individual risk.⁹

Therefore, the use of the most precise available methods in 1st trimester screening is of utmost importance.¹⁰

The biochemical assays Thermo Scientific™ B·R·A·H·M·S™ PAPP-A KRYPTOR™ and Thermo Scientific B·R·A·H·M·S Free β hCG KRYPTOR provide highly precise measurements and a consistent and excellent long-term performance.⁶

The analytical error has a great impact on the calculation of the risk in 1st trimester screening¹¹



Accurate dating of gestation and precise measurement of fetal nuchal translucency (NT)

Besides the measurement of the biochemical markers, the determination of ultrasound markers such as nuchal translucency (NT) and nasal bone (NB) at weeks 11-13 is the most important factor in first trimester aneuploidy screening. Again, accuracy in the measurement as well as the correct determination of the gestational age is essential for a correct risk calculation. A reliable result depends on the skills and experience of the ultrasound examiners and requires a high quality ultrasound device.¹²

It is recommended that a sonographer holds a certification of the Fetal Medicine Foundation (FMF)¹³ or a corresponding local organization.



The Fetal Medicine Foundation approval requires the commitment to the highest quality standard and an ongoing quality assurance. Thermo Scientific B·R·A·H·M·S serum markers and Thermo Scientific B·R·A·H·M·S KRYPTOR Systems fulfill these strict quality standards since 1999.


Proof of quality: Long-term precision data

The coefficient of variation (CV) is a measure for precision showing the extent of variability in relation to the mean. The lower the CV the higher the precision of the biomarker measurement.

PAPP-A and Free β hCG measured on KRYPTOR instruments provide the lowest mean CV and therefore the highest precision as shown by the external UK NEQAS data.⁶

PAPP-A


UK NEQAS Quality Data B-R-A-H-M-S PAPP-A KRYPTOR



3.1%
Mean CV

Internal QC Data B-R-A-H-M-S PAPP-A KRYPTOR


(>1500 samples, 88 kit lots, different calibrators and KRYPTOR platforms)



3.3%
Total CV


The outstanding precision and stability of the B·R·A·H·M·S prenatal screening assays is proved by the independent United Kingdom National External Quality Assessment Service (UK NEQAS)¹⁴ analysis since 2003.

UK NEQAS Quality Data B·R·A·H·M·S Free β hCG KRYPTOR



Internal QC Data B·R·A·H·M·S Free β hCG KRYPTOR

(>1500 samples, 84 kit lots, different calibrators and KRYPTOR platforms)




Reproducibility: A measure for quality

Influence of reproducibility on risk quality

Simulation to demonstrate the impact of the analytical variability on risk estimates:¹⁰

- Between-day variation of 1st trimester risk using the standard deviation for PAPP-A and Free β hCG measured on KRYPTOR was set as the reference.
- Hypothetical analytical systems (HAS) with standard deviations twice (HAS1) or three times higher (HAS2) than the ones for KRYPTOR were calculated.

Even a modest increase of the CV to 4-5% for a single marker lead to a CV for the risk of over 15%!



Adding PIGF to T21 screening strategies

Besides the proven benefits of Placental Growth Factor (PIGF) in first trimester pre-eclampsia screening¹⁵⁻¹⁸ this biomarker can also be intergrated into first trimester screening strategies for fetal aneuploidies. In the first trimester, **PIGF levels are significantly decreased** in pregnancies with a fetus affected by trisomy 21 compared to healthy controls.¹⁹

Implementation of PIGF in different screening strategies for trisomy 21 can either **increase the detection rate** or **decrease the false-positive rate**. In consequence, an improved false-positive rate results in a reduced number of women who will require an invasive test.¹⁹

Median placental growth factor multiples of the median in trisomy 21 and impact on performance of combined first-trimester screening in selected studies¹⁹

First-trimester studies on PIGF	Trisomy 21			Combined screening			
	n	GA (weeks)	Median PIGF-MoM	Without PIGF		With PIGF	
				FPR (%)	DR (%)	FPR (%)	DR (%)
Prospective							
Pandya et al. ²⁰	44	11–13	0.61	2.7	85	2.6	88
Retrospective							
Zaragoza et al. ²¹	90	11–13	0.71	3.0	60	3.0	67
Cowans et al. ²²	70	11–13	0.76	3.0	91	3.0	92
Koster et al. ²³	91	11–13	0.78	3.0	71	3.0	73
Kagan et al. ¹⁹	100	11–13	0.73	2.7	85	2.6	87
Koster et al. ²³	60	8–10	0.84	3.0	79	3.0	80

This improved screening performance can also be considered as an added benefit when screening for pre-eclampsia, where PIGF is used as a routine biomarker.

Thermo Scientific B·R·A·H·M·S prenatal screening biomarkers

High sensitivity and exceptional precision

Thermo Scientific B·R·A·H·M·S PAPP-A KRYPTOR

Automated immunofluorescent assay for the determination of pregnancy associated plasma protein-A (PAPP-A) in human serum and heparin plasma.

- **CE mark for trisomy and pre-eclampsia first trimester screening**
- **75 determinations per kit**
- **19 min incubation time**
- **Single-point calibration**
- **Wide measuring range: 0.004–90 IU/L**

B·R·A·H·M·S PAPP-A KRYPTOR provides an **outstanding precision** with a mean CV of only 3.1%, proven by UK NEQAS data 2003–2017.⁶

Thermo Scientific B·R·A·H·M·S Free β hCG KRYPTOR

Automated immunofluorescent assay for the determination of free beta subunit of human chorionic gonadotropin hormone (hCG) in human serum.

- **CE mark for trisomy screening in first and second trimester**
- **75 determinations per kit**
- **19 minutes incubation time**
- **Single-point calibration**
- **Wide measuring range: 0.16–50 000 IU/L**

B·R·A·H·M·S Free β hCG KRYPTOR provides an **outstanding precision** with a mean CV of only 3.0%, proved by UK NEQAS data 2003–2017.⁶





**Thermo Scientific
B·R·A·H·M·S PIGF plus KRYPTOR**

Automated immunofluorescent assay for the determination of placental growth factor (PIGF) in human serum. The assay is specific for the measurement of human free PIGF-1.

- **CE mark for trisomy and pre-eclampsia first trimester screening**
- **75 determinations per kit**
- **29 min incubation time**
- **Single-point calibration**
- **Wide measuring range: 3.6–7000 pg/mL**

With the lowest FAS and lowest cross-reactivity to other PIGF isoforms B·R·A·H·M·S PIGF plus KRYPTOR provides the **highest sensitivity** needed for reliably measuring low PIGF levels in the first trimester of pregnancy.²⁴



**Thermo Scientific
B·R·A·H·M·S KRYPTOR compact PLUS**

Exceptionally precise, fast and easy

Thermo Scientific B·R·A·H·M·S KRYPTOR compact PLUS

18 Years Reliable Results

18 Years Confident Decisions

- All KRYPTOR platforms FMF approved
- In routine use by FMF since 1999
- Excellent precision and proven median stability
- OSCAR compatible



The Fetal
Medicine Foundation



Thermo Scientific B·R·A·H·M·S Biomarkers Prenatal Screening Portfolio on KRYPTOR Systems

B·R·A·H·M·S AFP KRYPTOR	Art. no.: 816.075
B·R·A·H·M·S Free βhCG KRYPTOR	Art. no.: 809.075
B·R·A·H·M·S hCGα+β KRYPTOR	Art. no.: 841.050
B·R·A·H·M·S Inhibin A KRYPTOR***	Art. no.: 850.075
B·R·A·H·M·S PAPP-A KRYPTOR	Art. no.: 866.075
B·R·A·H·M·S PIGF plus KRYPTOR*	Art. no.: 859.075
B·R·A·H·M·S sFit-1 KRYPTOR*	Art. no.: 845.075
B·R·A·H·M·S uE3 KRYPTOR**	Art. no.: 803.075
B·R·A·H·M·S Fast Screen pre I plus Software	Art. no.: 105750

* Available on KRYPTOR compact PLUS and KRYPTOR GOLD

** Available on KRYPTOR, KRYPTOR compact PLUS and KRYPTOR GOLD

*** Available on KRYPTOR GOLD

References

1. Nicolaides KH. Prenat Diagn 2011; 31: 7-15
2. Kagan KO et al. Hum Reprod 2008; 23: 1968-1975
3. Akolekar R et al. Fetal Diagn Ther 2013; 33: 8-15
4. Poon LC et al. Fetal Diagn Ther 2013; 33: 16-27
5. Beta J et al. Fetal Diagn Ther 2011; 30: 88-93
6. Monthly UK NEQAS reports, February 2003 - April 2017
7. Wright D et al. Ultrasound Obstet Gynecol 2010; 36: 404-411
8. Spencer K et al. Presentation B·R·A·H·M·S KRYPTOR User Meeting, Cambridge, March 2007
9. Cuckle H. Coefficient of variance. DSNEWS 2007; 14(2): 25
10. Spencer K. Risk, a QC parameter. DSNEWS 2003; 10(1): 30-5
11. Wright D. Presentation at FMF World congress; June 2010
12. <https://fetalmedicine.org/training-n-certification/certificates-of-competence>
13. <https://fetalmedicine.org/>
14. <http://www.ukneqas.org.uk>
15. Poon LC et al. Ultrasound Obstet Gynecol 2010; 35: 662-70
16. Akolekar R et al. Prenat Diagn 2011; 31(1): 66-74
17. Poon LC et al. Prenat Diagn 2014; 34: 618-27
18. Akolekar R et al. Fetal Diagn Ther 2013; 33: 8-15
19. Kagan KO et al. Ultrasound Obstet Gynecol 2012; 40(5): 530-5
20. Pandya P et al. Fetal Diagn Ther 2012; 31(2): 87-93
21. Zaragoza E et al. Ultrasound Obstet Gynecol 2009; 33(4): 382-6
22. Cowans NJ et al. Ultrasound Obstet Gynecol 2011; 37(5): 515-9
23. Koster MP et al. Ultrasound Obstet Gynecol 2011; 38(2): 134-9
24. Nucci M et al. Fetal Diagn Ther 2014; 36(2): 106-16

Clinical Diagnostics Thermo Fisher Scientific +49 (0)3302 883 0
 B·R·A·H·M·S GmbH +49 (0)3302 883 100 fax
 Neuendorfstr. 25 info.brahms@thermofisher.com
 16761 Hennigsdorf www.thermoscientific.com/brahms
 Germany

Find out more at thermoscientific.com/brahms

Products are CE marked but not 510(k)-cleared and not available for sale in the U.S. Availability of products in each country depends on local regulatory marketing authorization status.

© 2018 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. KRYPTOR and TRACE are registered trademarks of Cisbio Bioassays, licensed for use by B·R·A·H·M·S GmbH, a part of Thermo Fisher Scientific. Nobel Prize is a registered trademark of the Nobel Foundation.

105036.18